Multiple System Atrophy: Clinical Trials

7 trials for Multiple System Atrophy, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting. 7 Phase 2, 2 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 27Recruiting 7
Phase 12Recruiting 2
Phase 32Recruiting 2

Follow Multiple System Atrophy: new trials by email Literature Review of Multiple System Atrophy trials Research Report on Multiple System Atrophy

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Tributyrin for Progressive Supranuclear Palsy (PSP): Virtual Trial
Tributyrin, Placebo - Parkinson Disease, Multiple System Atrophy
Phase 1 / Phase 2RecruitingPrabesh Kanel152026-10-012026-11-05
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy
3-N-butylphthalide - Multiple System Atrophy
Phase 2 / Phase 3RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine1502026-08-272026-10-16
An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy
TEV-56286 - Multiple System Atrophy
Phase 2RecruitingTeva Branded Pharmaceutical Products R&D LLC2002025-09-302026-10-09
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
Administration of Carbidopa/levodopa - Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic
Phase 1 / Phase 2RecruitingJulien Bally362025-07-182026-01-29
A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Foralumab Nasal - Multiple System Atrophy
Phase 2RecruitingTiziana Life Sciences LTD52025-05-192026-06-10
The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism
Nicotinamide Riboside, Placebo - Progressive Supranuclear Palsy, Multiple System Atrophy
Phase 2RecruitingHaukeland University Hospital3302024-03-052025-01-10
[18F]-MFBG Versus [123I]-MIBG and [18F]-PE2I in PD vs. MSA and DLB vs. AD
[18F]-MFBG PET CT, [18F]-FE-PE2I PET CT or PET MRI, [123I]-MIBG SPECT CT - Parkinson Disease, Dementia With Lewy Bodies
Phase 2 / Phase 3Recruitingprof. dr. Koen Van Laere1132024-01-192025-02-06

Narrower conditions

Parkinson Disease (3)  ·  Shy-Drager Syndrome (2)  ·  Supranuclear Palsy, Progressive (2)  ·  Alzheimer Disease (1)  ·  Corticobasal Degeneration (1)  ·  Dementia (1)  ·  Lewy Body Disease (1)  ·  Movement Disorders (1)  ·  Parkinsonian Disorders (1)  ·  Primary Dysautonomias (1)

Broader conditions

Autonomic Nervous System Diseases (7)  ·  Basal Ganglia Diseases (7)  ·  Brain Diseases (7)  ·  Central Nervous System Diseases (7)  ·  Nervous System Diseases (7)  ·  Neurodegenerative Diseases (7)  ·  Synucleinopathies (7)  ·  Movement Disorders (6)  ·  Primary Dysautonomias (6)  ·  Tauopathies (3)  ·  Cardiovascular Diseases (2)  ·  Cranial Nerve Diseases (2)  ·  Eye Diseases (2)  ·  Hypotension (2)

Interventions

3-n-butylphthalide (1)  ·  Levodopa (1)  ·  nicotinamide-beta-riboside (1)  ·  tributyrin (1)

Sponsors

Haukeland University Hospital (1)  ·  Julien Bally (1)  ·  Prabesh Kanel (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Teva Branded Pharmaceutical Products R&D LLC (1)  ·  Tiziana Life Sciences LTD (1)  ·  prof. dr. Koen Van Laere (1)

Countries

United States (3)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Israel (1)  ·  Italy (1)  ·  Japan (1)  ·  Norway (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Charalampos Tzoulis, MD, PhD (1)  ·  Jiali Pu, MD (1)  ·  Koen Van Laere (1)  ·  Prabesh Kanel, PhD (1)

Results publications

PMID 40924149

NIH funding

2023 (1), 2025 (1)